# Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

Study · id `cardio:ct-nct02072434` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02072434](<https://clinicaltrials.gov/study/NCT02072434>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02072434

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2199 participants.

## Technical summary

Registry record NCT02072434. Randomized; no masking; primary purpose treatment. Start 2014-03-25 (actual); primary completion 2016-02-03 (actual). Results posted on 2019-03-13.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2199 participants (enrolled count; ClinicalTrials.gov record NCT02072434, source copy `cardio:ctgov-nct02072434-2019-03-15`, retrieved 2026-10-26)
- Started: 2014-03-25 (actual) (ClinicalTrials.gov record NCT02072434, source copy `cardio:ctgov-nct02072434-2019-03-15`, retrieved 2026-10-26)
- Primary completion: 2016-02-03 (actual) (ClinicalTrials.gov record NCT02072434, source copy `cardio:ctgov-nct02072434-2019-03-15`, retrieved 2026-10-26)
- Completion: 2016-02-03 (actual) (ClinicalTrials.gov record NCT02072434, source copy `cardio:ctgov-nct02072434-2019-03-15`, retrieved 2026-10-26)
- Results first posted: 2019-03-13 (ClinicalTrials.gov record NCT02072434, source copy `cardio:ctgov-nct02072434-2019-03-15`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Bulgaria; Czechia; Denmark; France; Germany; Hungary; Israel; Italy; Netherlands; Poland; Romania; Russia; Spain; Sweden; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02072434, source copy `cardio:ctgov-nct02072434-2019-03-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02072434-2019-03-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
- Acronym: ENSURE-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Edoxaban
- Intervention (Drug): Warfarin
- Intervention (Drug): Enoxaparin
- Lead sponsor: Daiichi Sankyo
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial (`cardio:pubmed-27590218`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study (`cardio:pubmed-29947751`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 48350a115f029f2fa42d9ee54c34c735b84aa908e4fcd58146641dab2c83f951
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
